• By ICR Secretariat
  • Posted Thursday, June 10, 2021

Bristol Myers sued over delayed approval of cancer cell therapy


  • A bank representing former Celgene shareholders has sued Bristol Myers Squibb, claiming the pharmaceutical company failed to work diligently to win U.S. approval of a cancer cell therapy it acquired in its 2019 takeover of Celgene.